Tenoxicam (Tnx) a nonsteroidal anti-inflammatory dr ug belonging to the oxim poorly water soluble drug and the rate of its oral absorption is often controlled by the dissolution rate in the gastrointestinal tract. Hence it is necessary to increase the solubility of the Tenoxic am. Different liquisolid (LS) compacts were prepar ed using a mathematical model to calculate the required quanti ties of powder and liquid ingredients to produce ac ceptably flowable and compressible admixture. Liquisolid com pacts were prepared using tween 80 as non-volatile solvent, Avicel PH102 as carrier, and colloidal silicon diox ide (Aerosil 200) as the coating material. Several liquisolid tablets formulations containing various drug concen trations in liquid medication (ranging from 10% to 35% w/w) were prepared. The ratio of Avicel pH 102 (carrier) to Aerosil 200 (coating powder material) were kept (20, 25). The formulations were then evaluated for their flow properties such as bulk density, tapped density, c ompressibility index, angle of repose and Hausner’s ratio. FTIR, D SC, XRPD and SEM analysis were performed to know wh ether there is any interaction between drug and excipient s interactions and also to study the changes in dru g crystallinity and drug powder morphology. The liquisolid system s howed acceptable flow properties. The IR, XRPD and DSC studies demonstrated that there is no interaction b etween the drug and excipients. The tabletting prop erties of the liquisolid compacts were within the acceptable limi ts. Liquisolid compacts demonstrated higher drug re lease rates than those of conventional and marketed tablet wher e select formula F9( R25, 30%) due to increasing we tting properties and surface area of the drug. This study shows that liquisolid technique is a promising alt ernative for improvement of solubility and the dissolution rate of water insoluble drug.